What Is HIPEC (Hyperthermic Intraperitoneal Chemotherapy)?

HIPEC (Hyperthermic intraperitoneal chemotherapy – Heated intraperitoneal chemotherapy) is a treatment method called “Hyperthermic Intraperitoneal Chemotherapy” that has increasingly gained attention in cancer treatment in recent years.


Today, many different methods are used in the fight against cancer, and significant success has been achieved. In terms of both extending the patient’s lifespan and improving quality of life, the heated intraperitoneal chemotherapy procedure known as HIPEC is one of the important advances. In some cancers originating from intra-abdominal organs and in their advanced stages, intravenous (systemic) chemotherapy that is, cancer drugs, administered before surgical treatment (neoadjuvant treatment), after surgery (adjuvant treatment), or both before and after surgery may fail to provide the expected effect.

In this situation, the desired response to the treatments may not be achieved. Despite all these efforts, the disease may continue to progress, eventually impairing the patient’s quality of life and ultimately resulting in the loss of the patient. At the point where the desired response to treatment cannot be achieved, “heated intraperitoneal chemotherapy-HIPEC” emerges as a treatment option that may both extend life expectancy and improve quality of life.

Purpose of Chemotherapy Administration

The intra-abdominal organs and the abdominal wall are covered by a layer called the “peritoneum – abdominal membrane.” This structure covers both the surfaces of the intra-abdominal organs (visceral peritoneum) and the inner surface of the abdominal wall (parietal peritoneum). This thin layer lining the abdominal cavity provides lubrication for the organs through the small amount of fluid it secretes.

Cancer, while continuing to develop in the organ where it originates, tends to spread to other organs and areas as the disease progresses. Spread may occur through the blood, lymphatic system, direct extension to neighboring tissues, or dissemination into the abdominal cavity. In advanced stages of intra-abdominal cancers, tumor cells may spread to the peritoneum through direct extension and dissemination into the abdominal cavity. This is a condition seen in the final stage of cancer. Since the peritoneum does not have its own blood vessels, intravenously administered cancer-killing drugs may not reach the peritoneum at the desired concentrations, and treatment may therefore remain ineffective.

In this situation, the peritoneum invaded by the tumor should conceptually be considered as an organ, and the affected organ or organs should be removed together with the peritoneum in an effort to make the abdominal cavity macroscopically as tumor-free as possible. This procedure is called “cytoreductive surgery + peritonectomy.” Following these procedures, tumor-killing drugs (chemotherapeutic drug or drugs) heated to 42-43 degrees are delivered into the abdominal cavity using a special apparatus and system. Depending on the situation, this washing process is continued for 60-90 minutes, with the aim of eliminating tumor cells at the microscopic level as well.

Why Are Chemotherapy Drugs Administered Heated?

There are several reasons why anticancer drugs are administered into the abdominal cavity in a heated form. To list them: Heat facilitates the penetration of the drug into the tissues and increases the cancer-cell-killing effect of the selected chemotherapeutic agent.

In addition, heat itself has an anti-tumor effect, and it contributes to the even distribution of the drug across all surfaces within the abdominal cavity. During HIPEC, tumor cells are mechanically cleared from the surfaces of the small intestine and from within clot-fibrin layers.

For Which Diseases Is HIPEC Used?

When the peritoneum is involved, fluid begins to accumulate in the patient’s abdomen (ascites). This fluid may cause progressive abdominal swelling and, due to the pressure and tension it creates, may lead to problems with breathing and circulation. Sometimes it becomes so extensive that it prevents the patient from lying comfortably. It may also contribute to the spread of cancer cells to the diaphragm and other intra-abdominal areas. Although this fluid may occasionally be drained externally using a cannula or similar methods to relieve the patient, because the underlying pathology persists, the fluid usually accumulates again to the same level within a short period.

These are patients with advanced-stage cancer who may previously have been considered to have no further treatment options. Cytoreductive surgery and HIPEC are performed in this patient group with the aim of improving quality of life and extending survival.

The best results are most commonly obtained in diseases such as pseudomyxoma peritonei, which is a cancer involving the peritoneum itself, appendix cancer, and ovarian cancer in women. In addition, it has also begun to be used in colorectal tumors, stomach cancer, and more recently pancreatic cancers. When this type of treatment is performed, certain components should not be overlooked. The treatment becomes meaningful when all stages are carried out together.

For example, in patients with stomach cancer, treatment may begin with “Neoadjuvant Intraperitoneal and Systemic Chemotherapy – NIPS,” followed by gastric resection together with cytoreductive surgery + peritonectomy + HIPEC.

Treatment is then completed with systemic chemotherapy. HIPEC alone may be performed only for palliation, meaning to reduce symptoms to some extent, in patients with ascites whose general condition and disease are not suitable for cytoreductive surgery. In this situation, the procedure is performed through catheters placed laparoscopically into the abdominal cavity. It does not have a significant effect on survival time.

How Is HIPEC Performed?

In such an operation, the abdomen is opened along the midline from the xiphoid process to the pubis, and the entire abdominal cavity is evaluated. The affected peritoneum and other involved organs (ovary, large intestine, stomach, etc.) are removed together with the diseased organ, and complete or near-complete cytoreduction is performed through macroscopic tumor clearance. During these procedures, it may temporarily be necessary to bring the small or large intestine to the abdominal wall as a stoma. After treatment is completed, the intestine is returned to the abdominal cavity. Performing HIPEC alone without these procedures does not have much significance. On the other hand, performing cytoreductive surgery + peritonectomy alone also does not provide much benefit. These two components should complement each other. Cytoreductive surgery + peritonectomy + HIPEC should subsequently be supported with systemic chemotherapy.

HIPEC is performed following the clearance of intra-abdominal tumors. After tumor removal, a total of four drains are placed, two in the lower quadrants and two in the upper quadrants of the abdomen. The external ends of the drains are connected to the HIPEC device (a special device that heats the chemotherapy fluid). Two temperature probes are placed, one in the lower part of the abdomen and one in the upper part, to monitor the temperature level. In this way, while chemotherapy is being administered, the temperature is monitored to ensure that it remains at the desired constant level. The administered chemotherapy fluid should be maintained at 42-43 degrees Celsius. The amount of chemotherapy fluid administered is 3.5 liters. The washing process with the chemotherapy fluid lasts approximately 60-90 minutes. At the end of the procedure, the fluid inside the abdomen is withdrawn and the procedure is completed. All of these procedures and the operation itself require a considerable amount of time. This operation may last between 6 and 10 hours and requires thorough patient preparation together with an experienced team working in coordination.

```

In Which Situations Is HIPEC Not Performed?

HIPEC is not performed when there is involvement outside the abdominal cavity (brain, bones, lung metastases, etc.). If there are three or fewer metastatic lesions in the liver, these may be removed and HIPEC may be performed. However, HIPEC is also not indicated in cases of widespread liver metastases.

Another important organ is the small intestine. Since the small intestine is responsible for nutrient absorption within the digestive system, extensive small bowel resections are not compatible with life. Therefore, performing HIPEC in patients with widespread small bowel involvement does not provide much benefit.

```
```

```

Life Expectancy After HIPEC

Since the great majority of these patients have advanced-stage cancer, they are patients whose life expectancy may be limited to months. This important detail should not be overlooked, and it should be considered that the disease may not be completely treated and eliminated, but quality of life and life expectancy may be improved.

HIPEC has different long-term outcomes in cancers originating from different intra-abdominal organs. In pseudomyxoma peritonei, a cancer involving the peritoneum itself, the 5-year survival rate is approximately 66-97%. Among intra-abdominal organ cancers, ovarian cancers are among those in which the greatest benefit is obtained, with a 5-year survival rate of approximately 50%. In colorectal cancers, the 5-year survival rate is approximately 30% in appropriately selected cases.

The situation is somewhat different in stomach cancers, which generally have a poorer course compared with ovarian and colorectal cancers. While the one-year survival rate is 43%, the 5-year survival rate is unfortunately around . Considering that the expected survival time of patients with advanced-stage stomach cancer with peritoneal metastasis is normally approximately 6 months, the fact that 5-year survival can be discussed in a certain proportion of patients provides considerable insight into the success of the treatment applied.

Risks of HIPEC

The risk associated with cytoreductive surgery and HIPEC, which is a complex form of treatment, is higher than that of other elective standard operations. However, as mentioned previously, favorable results can be achieved in patients who are well prepared before surgery and carefully observed and monitored during the operation. Complications that may occur include bleeding during surgery, embolism (to the lungs, brain, etc.); chemotherapy-induced bone marrow failure, kidney failure, anastomotic separation and leakage, wound infection and dehiscence, and similar complications.

Such complications can be minimized in experienced centers through careful organization by experienced teams. Postoperative mortality, meaning the risk of losing the patient, appears at varying rates in the literature but is approximately 0-7% on average.
Considering the improvement in quality of life and survival achieved with this treatment method in such advanced and serious cancer cases, the potential complications and risk of death may be considered acceptable.